News – Page 60 – Selby Spine

SAN FRANCISCO, June 27, 2018 /PRNewswire/ —

The global ambulatory services market is expected to reach USD 4,099.6 billion by 2025, according to a new report by Grand View Research, Inc. Increase in the availability of technologically advanced products, increase in the incidence of chronic diseases, growth in ageing population, and technological advancements in surgeries to reduce cost & treatment time are among key factors likely to drive the market during the forecast period.

(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Ambulatory services are likely to witness high growth in the coming years due to increase in the number of surgeries, the availability of private & public funding, as well as the availability of same-day surgeries at low cost to offer better medical services. According to Healthcare Cost and Utilization Project (HCUP), in 2014, 17.2 million surgeries were performed in ambulatory surgical settings and 22 million surgeries in hospital outpatient settings. In addition, various mergers & acquisitions are anticipated to propel the market. For instance, in December 2015, Premier Emergency Medical Specialists was acquired by AmSurg. This acquisition was expected to help AmSurg enter the emergency medicine specialty.

Technological advancements pertaining to diagnosis and minimally invasive surgeries are likely to reduce complications and help shorten hospital stays. Homecare via e-visits and telehealth solutions have become viable components of ambulatory care. For instance, in January 2017, Arterys, Inc. received FDA approval to commercialize Arterys Cardio DL, the first technology that uses a cloud-based deep learning algorithm for cardiac imaging.

Browse full research report with TOC on “Ambulatory Services Market Size, Share & Trends Analysis Report By Type (Primary Care Offices, Emergency Departments, Surgical Specialty, Medical Specialty), By Region, And Segment Forecasts, 2018 – 2025“ at: https://www.grandviewresearch.com/industry-analysis/ambulatory-care-services-market

Further Key Findings From the Report Suggest:

Increase in government expenditure for the development of ambulatory facilities to increase accessibility and reduce treatment cost is expected to propel the market
Primary care offices accounted for the largest share of the market in 2016 due to cost-effective treatment and easy accessibility for diagnosis & treatment
Surgical specialty is anticipated to be the fastest-growing segment in the forecast period due to increase in the demand for minimally invasive procedures. In addition, the preference of patients for nonsurgical and minimally invasive surgeries has led to the growth of plastic surgery centers. According to American Society of Plastic Surgeons, in 2016, 7.6 million cosmetic procedures were performed on people aged between 40 and 54 years. In 2016, United Nations spent more than 15 billion dollars on esthetic surgical and nonsurgical procedures
Based on the region, North America held the largest market share and is expected to retain its dominance during the forecast period due to increase in the number of advanced diagnostic methods and rise in the number of cases related to orthopedics, ophthalmology, gastroenterology, plastic surgery, and chronic pain
The Asia Pacific region is likely to witness significant growth over the next decade due to increase in the incidence of angle closure glaucoma & myopia, increase in life expectancy, and growth in recognition of the need to develop emergency care outside traditional hospital settings
Some of the key players are Surgery Partners; Envision Healthcare; IntegraMed America, Inc.; Symbion, Inc.; Terveystalo; NueHealth; Aspen Healthcare; and Medical Facilities Corporation

Browse related reports by Grand View Research:

Vitamin D Testing Market – The global vitamin D testing market size was estimated at USD 498.1 million in 2016.
Cancer Biomarker Market – The global cancer biomarker market size was valued at USD 10.3 billion in the year 2016.
Biopsy Devices Market – The global biopsy devices market size was estimated at USD 1.0 billion in 2016.
Lung Cancer Therapeutics Market – The global lung cancer therapeutics market is expected to grow significantly over the forecast period.

Grand View Research has segmented the global ambulatory services market based on type and region:

Ambulatory Services Type (Revenue, USD Million, 2014 – 2025)
- Primary Care Offices
- Emergency Departments
- Surgical Specialty
  - Ophthalmology
  - Orthopedics
  - Gastroenterology
  - Pain Management/Spinal Injections
  - Plastic Surgery
  - Others
- Medical Specialty
Ambulatory Services Regional Outlook (Revenue, USD Million, 2014 – 2024)
- North America
  - U.S.
  - Canada
- Europe
  - UK
  - France
  - Germany
  - Spain
  - Italy
  - Switzerland
  - Netherlands
  - Belgium
- Asia Pacific
  - China
  - Japan
  - India
  - Australia
  - Thailand
  - South Korea
- Latin America
  - Brazil
  - Mexico
  - Colombia
- Middle East & Africa
  - South Africa
  - Saudi Arabia
  - United Arab Emirates

Explore the BI enabled intuitive market research database, The Grand Library, by Grand View Research, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of Californiaand headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

SOURCE Grand View Research, Inc.

LONDON, June 27, 2018 /PRNewswire/ — The Global Cartilage Repair Market size is expected to reach $7 billion by 2024, rising at a market growth of 5.6% CAGR during the forecast period.

Download the full report: https://www.reportbuyer.com/product/5446175

The tissue prevents friction between the bones, by absorbing shock in the joints. When damage is caused in the cartilage, it restricts the regular movement of the knee, causing immense pain. It generally occurs after a traumatic and twisting injury to the knee. If cartilage damage remains untreated, it would lead to knee replacement surgery.

The growth of the cartilage repair market can be attributed to changing lifestyle, leading to a number of disorders such as obesity and degenerative joint diseases. The aforementioned factors have an influence on cartilage related injuries. These injuries eventually hamper productivity among the working population. Growing epidemiology of such diseases need effective treatment options, driving the demand for regenerative medicine, which are used in restoring damaged cartilage.

Based on the modality, the Cartilage Repair market is segmented into Cell-Based and Non-Cell-Based. Cell-Based Cartilage Repair further segmented into Chondrocyte Transplantation and Growth Factor Technology. Non-Cell-Based Cartilage Repair further includes Tissue Scaffolds and Cell-Free Composites. Based on the Application, the market is segmented into Hyaline Cartilage and Fibrocartilage. The treatment type segment covers Palliative and Intrinsic Repair Stimulus. Palliative further segmented into Viscosupplementation and Debridement & Lavage. The site outlook segment covers Knee Cartilage Repair and others. Whereas, Knee Cartilage Repair covers Arthroscopic Chondroplasty, Autologous Chondrocyte, Osteochondral Grafts Transplantation, Cell-based Cartilage Resurfacing, Microfracture, and Other. Based on Regions, the Cartilage Repair market segments the market into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the Global Cartilage Repair Market. Key companies profiled in the report include B. Braun Melsungen AG, Zimmer Biomet, DePuy Synthes, Smith & Nephew plc, Stryker Corporation, Vericel Corporation, Osiris Therapeutics Inc., Arthrex, Inc., Collagen Solutions Plc, and Anika Therapeutics, Inc.

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer

Contacts

Exactech
Priscilla Bennett, 352-377-1140
Vice President of Corporate and Marketing Communications

Exactech’s Truliant(R) Knee System Honored as Winner in the Medical Design Excellence Awards. (Photo: Business Wire)

AUDUBON, Pa., June 26, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today a new clinical milestone with the successful implantation of over 3,000 screws using ExcelsiusGPS®, the company’s revolutionary robotic guidance and navigation system. Since the launch of ExcelsiusGPS® in late 2017, orthopedic and neurosurgeons have used the system with three compatible imaging modalities (preoperative CT, intraoperative CT, and fluoroscopic imaging) across a variety of spine surgery procedures to minimize radiation exposure, streamline workflow, and assist in screw placement. A recent white paper comparing robotic-assisted versus conventional screw placement demonstrates some of the benefits of this technology.

“Having completed installations and surgeon training programs through the first half of 2018, we see surgeons using this technology in open and minimally invasive spine procedures including posterior cervical fusion, sacroiliac joint fusion, and thoracolumbar fusion with posterior and single position lateral approaches,” said Chief Executive Officer Dave Demski. “Surgeons are realizing the benefits of the ExcelsiusGPS® platform and the potential to significantly improve surgical techniques as demonstrated in the recent cadaveric study.”

The study, led by Dr. Alexander R. Vaccaro, MD, Ph.D, M.B.A and performed by 10 board certified surgeons in a simulated surgical environment, evaluated pedicle screw placement time, accuracy, and radiation dose for ExcelsiusGPS® in open and MIS approaches compared to conventional surgical techniques. Results demonstrated the ExcelsiusGPS® robotic navigation significantly improved pedicle screw accuracy, allowed placement of larger screw diameters and lengths than conventional techniques, and reduced radiation exposure to the clinician. Additionally, ExcelsiusGPS® significantly reduced screw insertion time compared to the conventional MIS technique.

To learn more about the benefits of ExcelsiusGPS®, visit globusmedical.com/ExcelsiusGPS

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

FREMONT, Calif. – June 26, 2018 – Ceterix Orthopaedics, Inc., a leader in the development of cutting-edge surgical tools for orthopaedic surgeons, today announced the issuance of U.S. Patent No. 10,004,492 related to the company’s method of placing a suture around a tear to repair a damaged meniscus, adding to the company’s already expansive intellectual property portfolio.

Ceterix’s new patent further protects the company’s technology enabling surgeons to arthroscopically repair soft tissue injuries in the knee using minimally invasive techniques. This is the second set of method claims describing Ceterix’s proprietary Circumferential Compression Stitch (CCS), a suture method that provides uniform, anatomic compression of meniscus tears that was not possible to do previously given the tight constraints of the knee.

“Whether you are setting a broken bone or suturing a laceration, injuries heal best when the tissue edges are perfectly lined up and repaired without gaps,” says Dr. Justin Saliman, founder and chief medical officer of Ceterix. “For the first time, orthopaedic surgeons can now apply this principle to meniscus tears with NovoStitch^® Meniscal Repair Systems. We believe that by enabling simultaneous compression of the femoral and tibial sides of meniscus tears, the Ceterix technology can provide surgeons with greater confidence to repair tears that would have previously been considered non-repairable.”^[i],[ii]

“The invention of delivering a Circumferential Compression Stitch within the tight constraints of the knee may be the biggest innovation in meniscal repair in the last 15 years,” says John McCutcheon, president and CEO of Ceterix. “We are committed to expanding options for surgeons to preserve the meniscus and protect normal knee function in their patients.”

READ THE REST HERE

Stamford, CT, June 26, 2018 (GLOBE NEWSWIRE) — Dr. Brad Waddell is the first surgeon in Connecticut to offer HipAlign® for direct-anterior total hip replacement. HipAlign is a sensor-based navigation technology that helps surgeons perform precise and accurate hip replacement surgeries. The HipAlign system allows Dr. Waddell to offer his patients one of the most advanced surgical technologies available in Connecticut.

The HipAlign technology acts as a GPS for surgeons, using micro-electromechanical sensors like accelerometers and gyroscopes to guide hip replacement surgery, to ensure accuracy and alignment. All of this happens in a phone-like device that sits in the surgeon’s hands, and on their surgical instruments.

“Using HipAlign technology allows for accurate placement of the hip prosthesis by using patient’s individual pelvic anatomy,” said Dr. Waddell, Orthopedic Surgeon at Hospital for Special Surgery. “Cost-effective navigation and smart instrumentation like HipAlign is the future of technology in orthopedic surgery. It’s important in that the technology allows me to combine my clinical experience and decision making along with real-time data about my patient. The resulting precision may lead to improved outcomes for my patients.” Dr. Waddell works with OrthAlign in a personal capacity.

The HipAlign technology (manufactured by OrthAlign, Inc. a California-based company) launched in 2018, building on the legacy of KneeAlign®, a technology that has powered more than 75,000 surgeries to date.

To learn more about the HipAlign surgical procedure, visit www.orthalign.com.

ORTHALIGN, INC.

OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit www.orthalign.com or contact Adam Simone (asimone@orthalign.com).

Attachment

OrthAlignLogo_RGB_color

Adam Simone
OrthAlign
asimone@orthalign.com

26th June 2018

US spine care providers have a brand new tool to measure and improve patient care: a diagnosis-based clinical data registry that tracks patient care and outcomes.  Launched by the North American Spine Society (NASS), this web-based platform will allow health care providers to collect and analyse their spine care data and compare it to the de-identified data in the entire registry. Because it is diagnosis-specific, not procedure-specific, the NASS Spine Registry will enhance understanding of spine care treatments, their outcomes, and examine the natural history of spine disorders.

“In order to prove or disprove the effectiveness of spine treatments, the spine field needs to gather evidence,” says Zoher Ghogawala (Lahey Hospital & Medical Center, Burlington, USA), NASS research council director. “With its national reach and comprehensive nature, the NASS Spine Registry will help the spine care field make substantial progress on improving quality, developing best practices, and closing the gaps in medical evidence for spine care.”

From the initial idea to the implementation of a pilot program, the NASS Spine Registry was developed over the past eight years. NASS has made every effort to minimise potential barriers to participation, including cost, privacy concerns, administrative burden, and institutional review board (IRB) participation, a press release states.

“The really exciting and unique thing about the NASS registry is that it is multidisciplinary,” says Daniel Resnick (University of Wisconsin, Madison, USA), NASS president and chair of the NASS Registry Committee. “Despite the fact that more than 90% of spine care is managed without surgery, most existing registries are focused around surgical specialties or procedures. Thanks to the comprehensive nature of this registry, we will be able to see what care approaches are actually helping patients restore their function and reduce pain.”

READ THE REST HERE

NESS ZIONA, Israel, June 26, 2018 /PRNewswire/ —

CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that it has received grant approval from the Israel Innovation Authority (IIA) to finance continued development of the Company’s proprietary rhCollagen-based formulations intended for use as BioInk for the 3D printing of tissues and life savings organs. The total approved project budget is approximately $1.2 million (NIS 4.2 million), of which the Israel Innovation Authority will finance 30%, subject to certain conditions. The terms of the grant require, among other things, CollPlant to pay royalties to the IIA on future sales of any technology developed with these funds, up to the full grant amount.

“In addition to providing immediate non-dilutive funding, this grant from the Israel Innovation Authority represents an important validation of our BioInk technology and its market potential,” said Yehiel Tal, Chief Executive Officer of CollPlant. “With the recent opening of our new cGMP production facility in Rehovot, Israel, we are well positioned to meet growing demand for our BioInk and tissue repair products. We are grateful to the IIA for this recognition.”

About the Israel Innovation Authority

The Israel Innovation Authority, formerly known as the Office of the Chief Scientist of the Ministry of Economy (& MATIMOP), is an independent and impartial public entity that operates for the benefit of the Israeli innovation ecosystem and Israeli economy, as a whole. Its role is to nurture and develop Israeli innovation resources, while creating and strengthening the infrastructure and framework needed to support the entire knowledge industry.

About CollPlant

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. The Company’s products are based on its rhCollagen (recombinant human collagen) that is produced with its proprietary plant-based genetic engineering technology.

CollPlant’s products address indications for diverse fields of organ and tissue repair and are ushering in a new era in regenerative medicine. The Company’s flagship BioInk product line provides an ideal building block for 3D bioprinting of tissues and organs, and its unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

For more information, visit http://www.collplant.com

Safe Harbor Statement

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company’s expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen-based BioInk, VergenixSTR, and VergenixFG; the Company’s ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based BioInk, VergenixSTR, and VergenixFG, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company’s rhCollagen-based BioInk, VergenixSTR, and VergenixFG; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third-party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the Company’s reliance on third parties to conduct some aspects of its product manufacturing; the scope of protection we are able to establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company’s strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading “Risk Factors” included in CollPlant’s most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact at CollPlant:
Eran Rotem
Deputy CEO & Chief Financial Officer
Tel: +972-73-2325600/612
Email: Eran@collplant.com

IR Contact:
Amato and Partners, LLC
90 Park Avenue, 17th Floor
New York, NY 10016
admin@amatoandpartners.com

SOURCE CollPlant

SALT LAKE CITY, June 26, 2018 – Innovasis provided a business update related to recent organizational milestones.

Leadership Team Expansion

Innovasis is pleased to announce the recent expansion of their leadership team. Mike Wheelock was hired as Vice President of Sales and David Oka as Director of Business Development and Clinical Affairs.

“The addition of experienced industry veterans like David and Mike ensures Innovasis continues developing world-class distribution and supports our commitment to collect compelling clinical evidence for our evolving HA PEEK enhanced interbody platform,” said Innovasis President Mike English. “We are excited and honored to have them join our rapidly expanding team.”

Headquarters Groundbreaking

With continued company growth, Innovasis is excited to announce the groundbreaking of new headquarters in Salt Lake City, Utah. The 50,000 sq. ft. facility will include a two-station cadaver lab, in house manufacturing, and corporate offices.

“This move will allow us to train our surgeon and distribution partners in an extraordinary setting, expand our manufacturing capabilities, and create operational efficiencies crucial to remain competitive in this market,” commented English.

36^th Humanitarian Trip Completed

Innovasis completed their 36^th humanitarian trip to Lima, Peru. This is the second humanitarian trip the company has completed in 2018. “Our humanitarian mission the past six years includes a total of total of 60 surgeon participants and over 200 spine and cranial cases completed. We are grateful for the expert staff, surgeons, and nurses that make it possible for Innovasis to continue improving patient healthcare in Peru,” said English.

About Innovasis

Innovasis is a groundbreaking company engaged in the research, development, manufacturing, and marketing of spinal implant devices and related products. Innovasis offers a spinal product line with implants and instruments that address the major pathologies and focus areas of traditional spinal surgery.

June 25, 2018

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International N.V., (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the realignment of its strategic business units and the promotion of Brad Niemann to President of Global Orthofix Spine, which includes the BioStim, Spine Fixation, Spinal Kinetics and Biologics businesses. The Extremity Fixation business, which will now be referred to as “Orthofix Extremities” will continue to be led globally by Davide Bianchi as the President of Global Orthofix Extremities. This alignment structures Orthofix around two pillars: Spine and Extremities.

“In 2013, Orthofix segmented its business into four strategic business units to gain better strategic and management focus and drive needed performance improvements,” said Orthofix President and Chief Executive Officer, Brad Mason. “This strategy has proved very successful over the last several years and resulted in each business performing well with solid leadership, execution and growth.

“Today we are announcing these organizational changes as part of an overall strategy to position the Company for growth acceleration and to realize opportunities that can only be achieved by leveraging our full portfolio of spine solutions,” Mason continued. “As we expand our product offerings and integrate new technologies, such as the M6^® disc, we believe the time is right to further optimize our structure to better serve our surgeon customers through a two-pillar approach of a consolidated Spine group and a focused Extremities business. We are fortunate to have two extremely talented executives to lead these organizations.”

“I am excited to have the opportunity to lead the Spine group and look forward to working more closely with the current management teams from all the spine product areas,” said Brad Niemann, President of Global Orthofix Spine. “This structure will foster better collaboration and alignment by bringing these teams together under one umbrella to help ensure we make the most of our many opportunities in the market.”

Orthofix will continue to report its financial performance according to the current four strategic business unit structure until completion of this transition, which is expected to be at the beginning of 2019. Subsequently, the Company will evaluate what changes in the Company’s segment financial reporting, if any, may be required as a result of this transition. In any event, the Company will continue to provide revenue transparency into the extremities, stimulation, spine hardware, biologics and Spinal Kinetics product groups.

About Brad Niemann

Niemann joined Orthofix in 2012 as Senior Vice President, Commercial Operations and was quickly promoted to President of the BioStim strategic business unit in June 2013 where he has successfully led the efforts to expand the utilization of bone growth stimulation technology. Prior to Orthofix, he worked in a variety of management and leadership roles of increasing responsibility at DJO Global, Inc. including serving as Senior Vice President, Recovery Sciences where he led their commercial efforts. As President of Global Orthofix Spine, he will work with the leaders of the Orthofix spine businesses in the development of strategies and initiatives to advance the Company’s worldwide spine business.

About Orthofix

Orthofix International N.V. is a global medical device company focused on musculoskeletal products and therapies. The Company’s mission is to improve patients’ lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in over seventy countries via the Company’s sales representatives and distributors. For more information, please visit www.orthofix.com.

Contacts

Orthofix International N.V.
Investor Relations
Mark Quick, 214-937-2924
markquick@orthofix.com
or
Media Relations
Denise Landry, 214-937-2529
deniselandry@orthofix.com

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

Ambulatory Services Market Size Worth USD 4,099.6 Billion by 2025: Grand View Research, Inc.

The Global Cartilage Repair Market size is expected to reach $7 billion by 2024, rising at a market growth of 5.6% CAGR during the forecast period

Related Links

Exactech’s Truliant® Knee System Honored as Winner in the Medical Design Excellence Awards (MDEA)

Contacts

Globus Medical Announces ExcelsiusGPS® Milestone: 3,000 screws implanted

Ceterix® Orthopaedics Awarded New Patent for Circumferential Suturing Method in Meniscus Repair

Bradford S. Waddell, M.D. Becomes First Surgeon In Connecticut to Implement HIPALIGN®, Handheld Sensor-based Navigation for DA Total Hip Surgery

NASS launches multidisciplinary Spine Registry to “Collect, measure, care”

CollPlant Receives Research and Development Project Approval From the Israel Innovation Authority to Advance its Collagen-based BioInk for 3D Printing of Tissues and Organs

Innovasis Provides Business Update

Orthofix Realigns Business Unit Structure, Names Brad Niemann President of Global Orthofix Spine and Davide Bianchi President of Global Orthofix Extremities

Contacts

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS